Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Average PT from Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $4.00.

MCRB has been the topic of a number of research reports. The Goldman Sachs Group dropped their target price on shares of Seres Therapeutics from $1.00 to $0.75 and set a "sell" rating on the stock in a report on Friday. StockNews.com upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, March 6th.

Seres Therapeutics Stock Performance

Shares of NASDAQ:MCRB traded up $0.00 during trading on Friday, reaching $0.74. The company had a trading volume of 1,073,547 shares, compared to its average volume of 1,374,588. The firm's fifty day moving average is $0.79 and its 200 day moving average is $0.83. The firm has a market capitalization of $128.67 million, a PE ratio of -3.23 and a beta of 2.19. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53.

Remove Ads

Institutional Investors Weigh In On Seres Therapeutics

Large investors have recently made changes to their positions in the company. Avantax Advisory Services Inc. raised its holdings in shares of Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 28,500 shares during the period. Jane Street Group LLC increased its stake in Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after buying an additional 37,866 shares during the period. Virtu Financial LLC increased its stake in Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after buying an additional 18,191 shares during the period. Providence Wealth Advisors LLC increased its stake in Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock valued at $93,000 after buying an additional 22,250 shares during the period. Finally, Northern Trust Corp increased its stake in Seres Therapeutics by 20.4% in the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after buying an additional 44,461 shares during the period. Institutional investors and hedge funds own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.